



State of Utah

GARY R HERBERT
Governor

SPENCER J. COX
Lieutenant Governor

Utah Department of Health Executive Director's Office

Joseph K. Miner, M.D., M.S.P.H., F.A.C.P.M.
Executive Director

Marc E. Babitz, M.D.
Deputy Director

Nate Checketts
Deputy Director
Director, Medicaid and Health Financing

Utah Statewide Standing Order Dispensing Naloxone for Opioid Overdose Prevention

Purpose:

Opioid overdose deaths are the leading cause of poisoning death in Utah and the death rate from opioid overdose in Utah is among the highest in the U.S. In 2014, 300 people died in Utah of an opioid overdose due to either a prescription opioid or an illicit opioid such as heroin.

Opioid overdose can be reversed and death prevented by timely administration of naloxone which is an opioid antagonist. As authorized by State law, this standing order is intended to increase access to naloxone for those who might be at risk of an overdose or who might be in a position to assist somebody at risk of an overdose.

Authority:

Pursuant to the authority provided in UCA §26-55-105(2), this standing order authorizes a pharmacist licensed under UCA §58-17b Pharmacy Practice Act to dispense naloxone according to the provisions of UCA §26-55-105 and R156-17b-625 and the requirements of this standing order.

Immunity:

UCA §26-55-105 provides protection from civil liability for a pharmacist who dispenses naloxone according to this standing order.

Dispensing Guidelines:

Who may receive naloxone under this standing order:

- An individual who is at increased risk of experiencing an opioid overdose
- A family member, friend or other person who could assist an individual at increased risk of an opioid overdose, including an individual on behalf of:
 - A law enforcement agency;
 - The Utah Department of Health;
 - A Utah local health department;
 - An organization that provides substance abuse or mental health treatment, recovery or support services;
 - An organization that provides services to the homeless;
 - An organization that provides training in proper administration of naloxone;
 - An organization that provides harm reduction services; or
 - A school

- An individual on behalf of an overdose outreach provider for use as provided in UCA §26-55-106

Naloxone products that may be dispensed under this standing order:

Nasal administration

- Narcan® Nasal Spray (naloxone HCl) 4 mg/0.1mL Nasal Spray
 - Dispense one (1) box containing two (2) 4 mg/0.1 mL doses of naloxone
 - Instructions: Spray 0.1 mL into one nostril. Repeat with second device into the other nostril after 2-3 minutes if no or minimal response. Call 911 and/or transport to hospital.
- Naloxone HCl Solution 1 mg/mL in a 2 mL pre-filled Luer-Lock Syringe
 - Dispense: 2 x 2 mL syringes (4 mL total) with two nasal mucosal atomization devices
 - Instructions: Spray 1 mL (1/2 of syringe) into each nostril. Repeat after 2-3 minutes if no or minimal response. Call 911 and/or transport to hospital.

Intramuscular (IM) administration

- Evzio® (naloxone HCl injection) 0.4 mg autoinjector
 - Dispense one box containing two auto-injectors
 - Inject into outer thigh as directed by the English voice-prompt system. Place black side firmly on outer thigh and depress and hold for 5 seconds. Repeat with second device in 2-3 minutes if no or minimal response. Call 911 and/or transport to hospital.
- Naloxone HCl 0.4 mg/mL in a 1 mL unit dose vial
 - Dispense: 2 x 1 mL unit dose vials and two (2) 3cc syringes with 23-25G 1-1.5 inch needles for intramuscular injection.
 - Instructions: Inject 1 mL in shoulder or thigh. Repeat after 2-3 minutes if no or minimal response. Call 911 and/or transport to hospital.

Prices vary widely for the different products and reimbursement practices vary by insurer. Information on Medicaid reimbursement can be obtained at: <https://naloxone.utah.gov>.

Dispense at least 2 doses of naloxone to an individual or an appropriate amount for the needs of an organization that will further distribute it. Refills may be dispensed under this standing order.

Reporting:

As required in R156-17b-625, the pharmacist-in-charge (or a responsible corporate officer) for each pharmacy licensee that dispenses naloxone under this standing order shall affirm that the pharmacy licensee has complied with the protocol in UCA §26-55-105 and shall report the following information:

- The total number of single doses of naloxone dispensed during the reporting period, and
- The name of each naloxone product dispensed along with the total number of single doses of that particular product.

The report must be submitted to the Utah Department of Health at <https://naloxone.utah.gov> and is due no later than 10 days after December 31 of each calendar year.

Registration:

Pharmacies that plan to dispense naloxone under this standing order are asked to voluntarily register with the Utah Department of Health at: <https://naloxone.utah.gov>.

Records:

In addition to any other requirements under Utah or federal law, the pharmacy licensee must keep the data specified in R156-17b-625(5).

Educational Materials:

Educational materials to provide to an individual when naloxone is dispensed and educational materials for dispensers, in addition to other information about naloxone, can be found at <https://naloxone.utah.gov>.

Effective Period for this Order:

This standing order will be reviewed as new information becomes available and will be updated if needed or at least every 2 years.

Joseph K. Miner, MD

Joseph K. Miner, MD, MSPH
Executive Director
Utah Department of Health

December 8, 2016

Date